Pasithea Therapeutics Corp (KTTA)

$0.80 +0.00 (0.16%)
Market Cap 18.47M
Revenue (ttm) 0.00
Net Income (ttm) -13.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 231,500
Avg Vol 288,800
Day's Range N/A - N/A
Shares Out 23.09M
Stochastic %K 56%
Beta 0.21
Analysts Sell
Price Target $3.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
mda2015
mda2015 Feb. 20 at 11:45 AM
$KTTA
0 · Reply
Boketaw
Boketaw Feb. 19 at 8:39 PM
$KTTA up. I am long!!
0 · Reply
DHHF
DHHF Feb. 19 at 8:09 PM
$KTTA 👀
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 5:53 PM
$KTTA Current Stock Price: $0.71
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 3:11 PM
$KTTA RSI: 18.61, MACD: -0.0707 Vol: 0.08, MA20: 0.81, MA50: 0.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MarketRegimes
MarketRegimes Feb. 17 at 1:34 PM
$KTTA Obscure micro-cap; likely a shell.
0 · Reply
FadeLars
FadeLars Feb. 17 at 8:54 AM
$KTTA Obscure micro-cap; likely illiquid
0 · Reply
DumpDeflector
DumpDeflector Feb. 9 at 3:46 PM
$KTTA Kura or biotech; name not standard, indicating high risk.
0 · Reply
Eventinvestor
Eventinvestor Feb. 6 at 7:03 PM
$BGMS 🫣🫣🫣🫣🫣🫣🫣🫣🫣🫣$FLYE $KTTA $SMX $YXT
0 · Reply
OAppelquist
OAppelquist Jan. 26 at 6:02 PM
$KTTA the Registrant hereby terminates the effectiveness of the Registration Statement. In addition, in accordance with undertakings made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any securities being registered which remain unsold at the termination of the offering, the Registrant hereby removes from registration all securities registered under the Registration Statement that remain unsold under the Registration Statement as of the date hereof. https://ir.pasithea.com/sec-filings/all-sec-filings##document-546-0001213900-26-007469-1
1 · Reply
Latest News on KTTA
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 7:01 AM EST - 6 days ago

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Jan 13, 2026, 7:01 AM EST - 5 weeks ago

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dec 2, 2025, 7:00 AM EST - 2 months ago

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Nov 28, 2025, 9:20 AM EST - 3 months ago

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Nov 24, 2025, 7:00 AM EST - 3 months ago

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Nov 21, 2025, 12:35 PM EST - 3 months ago

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Nov 20, 2025, 4:01 PM EST - 3 months ago

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Nov 4, 2025, 7:03 AM EST - 3 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Sep 16, 2025, 7:03 AM EDT - 5 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:39 AM EDT - 6 months ago

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jul 31, 2025, 7:01 AM EDT - 7 months ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 11, 2025, 7:02 AM EDT - 9 months ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Jun 2, 2025, 8:02 AM EDT - 9 months ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 20, 2025, 7:01 AM EDT - 9 months ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 14, 2025, 7:02 AM EDT - 10 months ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 7, 2025, 5:00 PM EDT - 10 months ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 10 months ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

May 6, 2025, 9:29 AM EDT - 10 months ago

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

May 6, 2025, 7:03 AM EDT - 10 months ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 29, 2025, 7:02 AM EDT - 10 months ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 24, 2025, 7:02 AM EDT - 10 months ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Apr 10, 2025, 7:02 AM EDT - 11 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Jan 14, 2025, 8:02 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 8:56 AM EDT - 1 year ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 9:11 AM EDT - 1 year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 28, 2024, 6:59 AM EDT - 1 year ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Apr 24, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Feb 13, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 8, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Jan 2, 2024, 8:35 AM EST - 2 years ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 28, 2023, 5:00 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 19, 2023, 5:19 PM EST - 2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Dec 11, 2023, 8:01 AM EST - 2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 4:27 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 29, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 4:14 PM EDT - 2 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Aug 1, 2023, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:43 AM EDT - 2 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Jul 20, 2023, 8:40 AM EDT - 2 years ago

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Jun 30, 2023, 9:28 AM EDT - 2 years ago

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Jun 1, 2023, 7:57 AM EDT - 2 years ago

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

mda2015
mda2015 Feb. 20 at 11:45 AM
$KTTA
0 · Reply
Boketaw
Boketaw Feb. 19 at 8:39 PM
$KTTA up. I am long!!
0 · Reply
DHHF
DHHF Feb. 19 at 8:09 PM
$KTTA 👀
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 5:53 PM
$KTTA Current Stock Price: $0.71
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 3:11 PM
$KTTA RSI: 18.61, MACD: -0.0707 Vol: 0.08, MA20: 0.81, MA50: 0.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MarketRegimes
MarketRegimes Feb. 17 at 1:34 PM
$KTTA Obscure micro-cap; likely a shell.
0 · Reply
FadeLars
FadeLars Feb. 17 at 8:54 AM
$KTTA Obscure micro-cap; likely illiquid
0 · Reply
DumpDeflector
DumpDeflector Feb. 9 at 3:46 PM
$KTTA Kura or biotech; name not standard, indicating high risk.
0 · Reply
Eventinvestor
Eventinvestor Feb. 6 at 7:03 PM
$BGMS 🫣🫣🫣🫣🫣🫣🫣🫣🫣🫣$FLYE $KTTA $SMX $YXT
0 · Reply
OAppelquist
OAppelquist Jan. 26 at 6:02 PM
$KTTA the Registrant hereby terminates the effectiveness of the Registration Statement. In addition, in accordance with undertakings made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any securities being registered which remain unsold at the termination of the offering, the Registrant hereby removes from registration all securities registered under the Registration Statement that remain unsold under the Registration Statement as of the date hereof. https://ir.pasithea.com/sec-filings/all-sec-filings##document-546-0001213900-26-007469-1
1 · Reply
FearlessAlex
FearlessAlex Jan. 24 at 9:23 PM
$KTTA In early December 2025, Pasithea announced the closing of a $60 million public offering of common stock (priced around 75 cents per share earlier in the process). This provided significant capital for ongoing clinical programs.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 19 at 6:52 PM
$KTTA RSI: 35.17, MACD: -0.0374 Vol: 0.13, MA20: 1.06, MA50: 0.96 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UtahSUV
UtahSUV Jan. 17 at 1:52 AM
$KTTA can this shit do anything besides rob shareholders
0 · Reply
DARKP00L
DARKP00L Jan. 13 at 12:37 PM
$KTTA 07:08 on Jan. 13 2026 Pasithea Therapeutics Provided Updated Timelines on Its Ongoing Clinical Trials in Advanced Cancer and Adult NF1-PN Patients #tradeideas
0 · Reply
Sw1ngb0t
Sw1ngb0t Jan. 11 at 2:35 AM
$KTTA $1.44+
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 10 at 6:48 AM
$KTTA
0 · Reply
Risky_Behavoir
Risky_Behavoir Dec. 31 at 6:52 PM
$KTTA this one needs some kind of news. Otherwise it will trade sideways till they R\S
0 · Reply
Charles927
Charles927 Dec. 31 at 5:30 PM
$KTTA S☀️☀️N‼️💪🏾 EXTREMELY
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 30 at 10:16 PM
$KTTA Current Stock Price: $1.16
0 · Reply
PayoffPro
PayoffPro Dec. 26 at 8:58 AM
$KTTA This name increasingly trades on execution rhythm rather than speculation about possibilities. Execution gaps should narrow meaningfully. Momentum stabilizes only when delivery becomes predictable. Proof, rather than potential, becomes the key differentiator.
0 · Reply